XBiotech Inc. (XBIT)Healthcare | Biotechnology | Austin, United States | NasdaqGS
2.27 USD
-0.03
(-1.304%) ⇩
(Aug. 28, 2026, 4 p.m.
EDT)
After hours: 2.29 +0.02 (0.881%) ⇧ (Aug. 28, 2026, 7:30 p.m. EDT) |
Hot Take ↕ | Aug. 22, 2026, 1:34 a.m. EDT
The investment case here is severely compromised by a deteriorating business reality. The company is burning cash aggressively, with operating and free cash flows both deeply negative, and returns on assets and equity are substantially negative. While the stock trades at a discount to book value, this is likely a reflection of the poor quality of assets or the inability to generate earnings rather than a margin of safety. The price history confirms this structural weakness, showing a catastrophic 79% decline over the last nine years, with the most recent annual performance being another sharp drop. There is no evidence of a turnaround in revenue or profitability. Furthermore, the options market is screaming caution, with traders buying insurance against further declines rather than betting on a rally. Without a credible path to profitability or a clear catalyst for recovery, this remains a speculative trap. |
| Model | MAE |
|---|---|
| AutoARIMA ✓ | 0.036106 |
| AutoETS | 0.036508 |
| MSTL | 0.037066 |
| AutoTheta | 0.042344 |
Forecast horizon: 45 days | Selected: AutoARIMA
| Forecast Reliability | |
|---|---|
| Score | 51% |
| H-stat | 7.94 |
| Ljung-Box p | 0.000 |
| Jarque-Bera p | 0.373 |
| Excess Kurtosis | -0.98 |
| Attribute | Value |
|---|---|
| Sector | Healthcare |
| Ex Dividend Date | 2021-07-14 |
| Last Dividend Date | 2021-07-14 |
| Market Cap | 69,207,152 |
| Forward P/E | 17.46 |
| Beta | 0.85 |
| Website | https://www.xbiotech.com |
As of Aug. 22, 2026, 1:34 a.m. EDT: Speculators are overwhelmingly positioning for downside protection, evidenced by massive open interest and volume in in-the-money puts compared to virtually zero call activity. Implied volatility is significantly higher for puts (4.5%) than calls (1.97%), indicating a sharp skew in fear. The lack of any out-of-the-money call positioning suggests no speculative bets on a breakout, while the heavy put concentration at the $2.50 strike acts as a significant floor defense.
| Date | Dividend | Yield % |
|---|---|---|
| 2021-07-15 | 2.5 | 15.087508 |
| Attribute | Value |
|---|---|
| 52 Week Change | -0.23841059 |
| Address1 | 5,217 Winnebago Lane |
| All Time High | 32.5 |
| All Time Low | 2.09 |
| Ask | 2.96 |
| Ask Size | 2 |
| Average Daily Volume10 Day | 30,460 |
| Average Daily Volume3 Month | 34,488 |
| Average Volume | 34,488 |
| Average Volume10Days | 30,460 |
| Beta | 0.847 |
| Bid | 1.67 |
| Bid Size | 2 |
| Book Value | 4.214 |
| City | Austin |
| Compensation As Of Epoch Date | 1,767,139,200 |
| Country | United States |
| Crypto Tradeable | 0 |
| Currency | USD |
| Current Price | 2.27 |
| Current Ratio | 33.152 |
| Custom Price Alert Confidence | HIGH |
| Date Short Interest | 1,786,665,600 |
| Day High | 2.32 |
| Day Low | 2.26 |
| Display Name | XBiotech |
| Dividend Date | 1,626,998,400 |
| Earnings Timestamp End | 1,755,259,200 |
| Earnings Timestamp Start | 1,754,909,940 |
| Ebitda | -46,780,000 |
| Ebitda Margins | 0.0 |
| Enterprise To Ebitda | 0.862 |
| Enterprise Value | -40,320,852 |
| Eps Forward | 0.13 |
| Eps Trailing Twelve Months | -1.46 |
| Esg Populated | 0 |
| Ex Dividend Date | 1,626,307,200 |
| Exchange | NMS |
| Exchange Data Delayed By | 0 |
| Exchange Timezone Name | America/New_York |
| Exchange Timezone Short Name | EDT |
| Fax | 512 386 5505 |
| Fifty Day Average | 2.2999 |
| Fifty Day Average Change | -0.029900074 |
| Fifty Day Average Change Percent | -0.013000597 |
| Fifty Two Week Change Percent | -23.841059 |
| Fifty Two Week High | 3.44 |
| Fifty Two Week High Change | -1.1700001 |
| Fifty Two Week High Change Percent | -0.3401163 |
| Fifty Two Week Low | 2.09 |
| Fifty Two Week Low Change | 0.18000007 |
| Fifty Two Week Low Change Percent | 0.086124435 |
| Fifty Two Week Range | 2.09 - 3.44 |
| Financial Currency | USD |
| First Trade Date Milliseconds | 1,429,104,600,000 |
| Float Shares | 22,837,750 |
| Forward Eps | 0.13 |
| Forward P E | 17.461538 |
| Free Cashflow | -28,495,876 |
| Full Exchange Name | NasdaqGS |
| Full Time Employees | 87 |
| Fullday Change | -0.03 |
| Fullday Change Percent | -1.30435 |
| Fullday Price | 2.29 |
| Gmt Off Set Milliseconds | -14,400,000 |
| Gross Margins | 0.0 |
| Has Pre Post Market Data | 1 |
| Held Percent Insiders | 0.24327 |
| Held Percent Institutions | 0.06735 |
| Implied Shares Outstanding | 30,487,731 |
| Industry | Biotechnology |
| Industry Disp | Biotechnology |
| Industry Key | biotechnology |
| Is Earnings Date Estimate | 1 |
| Language | en-US |
| Last Dividend Date | 1,626,307,200 |
| Last Dividend Value | 2.5 |
| Last Fiscal Year End | 1,767,139,200 |
| Long Business Summary | XBiotech Inc., a biopharmaceutical company, discovers, and develops, True Human monoclonal antibodies for treating various diseases. It develops a pipeline of product candidates targeting inflammatory and infectious diseases. The company is also developing interleukin-1 alpha therapies to various medical conditions, such as cancer, stroke, heart attack, or arthritis; and mediates tissue breakdown, angiogenesis, the formation of blood clots, malaise, muscle wasting, and general inflammation. The company was incorporated in 2005 and is headquartered in Austin, Texas. |
| Long Name | XBiotech Inc. |
| Market | us_market |
| Market Cap | 69,207,152 |
| Market State | CLOSED |
| Max Age | 86,400 |
| Message Board Id | finmb_216818432 |
| Most Recent Quarter | 1,782,777,600 |
| Net Income To Common | -45,133,000 |
| Next Fiscal Year End | 1,798,675,200 |
| Non Diluted Market Cap | 70,121,781 |
| Open | 2.32 |
| Operating Cashflow | -40,695,000 |
| Operating Margins | 0.0 |
| Payout Ratio | 0.0 |
| Phone | 512 386 2900 |
| Post Market Change | 0.01999998 |
| Post Market Change Percent | 0.8810564 |
| Post Market Price | 2.29 |
| Post Market Time | 1,787,959,806 |
| Previous Close | 2.3 |
| Price Hint | 4 |
| Price To Book | 0.53868055 |
| Profit Margins | 0.0 |
| Quick Ratio | 32.752 |
| Quote Source Name | Nasdaq Real Time Price |
| Quote Type | EQUITY |
| Recommendation Key | none |
| Region | US |
| Regular Market Change | -0.029999971 |
| Regular Market Change Percent | -1.3043466 |
| Regular Market Day High | 2.32 |
| Regular Market Day Low | 2.26 |
| Regular Market Day Range | 2.26 - 2.32 |
| Regular Market Open | 2.32 |
| Regular Market Previous Close | 2.3 |
| Regular Market Price | 2.27 |
| Regular Market Time | 1,787,947,200 |
| Regular Market Volume | 6,960 |
| Return On Assets | -0.19298 |
| Return On Equity | -0.29936 |
| Sand P52 Week Change | 0.20504117 |
| Sector | Healthcare |
| Sector Disp | Healthcare |
| Sector Key | healthcare |
| Shares Outstanding | 30,487,731 |
| Shares Percent Shares Out | 0.0109 |
| Shares Short | 332,975 |
| Shares Short Previous Month Date | 1,784,073,600 |
| Shares Short Prior Month | 281,470 |
| Short Name | XBiotech Inc. |
| Short Percent Of Float | 0.0128 |
| Short Ratio | 9.55 |
| Source Interval | 15 |
| State | TX |
| Symbol | XBIT |
| Total Cash | 109,528,000 |
| Total Cash Per Share | 3.593 |
| Total Debt | 0 |
| Tradeable | 0 |
| Trailing Annual Dividend Rate | 0.0 |
| Trailing Annual Dividend Yield | 0.0 |
| Trailing Eps | -1.46 |
| Trailing Peg Ratio | None |
| Triggerable | 1 |
| Two Hundred Day Average | 2.398675 |
| Two Hundred Day Average Change | -0.12867498 |
| Two Hundred Day Average Change Percent | -0.053644195 |
| Type Disp | Equity |
| Volume | 6,960 |
| Website | https://www.xbiotech.com |
| Zip | 78,744 |